DropGenie announced the closing of its Seed+ financing round to support the launch of its first product. The round was led by Skeleton Key. New investors Merck Global Health Innovation Fund and CQDM also joined the financing, with continued participation from existing investors Real Ventures and Anges Québec.
DropGenie is a biotechnology company developing next-generation gene editing workflows. The company’s platform enables high-throughput, miniaturized gene editing workflows designed to reduce the number of cells and reagents required per experiment.
The new funding will support commercialization efforts, including scaling manufacturing, building commercial operations, and accelerating customer adoption.
The product rollout follows validation through DropGenie’s Early Access Program, with major global pharma, biotech, and research customers already integrating the company’s technology into their workflows.
DropGenie said its platform enables direct edits on primary patient cells, helping researchers generate more biologically relevant insights earlier in the research and development process.
The company said its miniaturized workflows can lower costs, accelerate editing turnaround time, and support applications across cell therapy, functional genomics, and AI-driven discovery.
The Seed+ financing will also support DropGenie’s strategic data partnerships with customers. These partnerships are designed to generate high-quality, standardized gene editing data that can serve as foundational datasets for data-driven discovery in cell therapy and functional biology.
DropGenie is based in Montreal and Boston.
KEY QUOTES:
“The most powerful insights in biology come from perturbations—changing one thing and watching how a living system responds. But capturing those signals with fidelity demands working at the right scale, in the right cells. Our platform miniaturizes workflows and lowers cell requirements to enable direct editing of primary patient cells—giving researchers access to true biological readouts previously impossible to capture. This opens the door to faster, more predictive development across cell therapy, functional genomics, and beyond.”
Alison Hirukawa, CEO and Co-Founder of DropGenie
“We find the DropGenie platform’s ability to reliably miniaturize and accelerate experimental workflows via automation to be extremely compelling. Being able to capture every parameter variation of these complex gene editing experimental processes creates the data we need to fundamentally accelerate innovation and to better leverage AI beyond the theoretical discovery phases. This is exactly the kind of science technology Skeleton Key wants to support and see succeed.”
Ann Lai, Managing Partner of Skeleton Key
